Efficacité des psychédéliques en psychiatrie, une revue systématique

Organisation mondiale de la santé, 2001 Kessler, 2012, Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States, Int J Methods Psychiatr Res, 21, 169, 10.1002/mpr.1359 Smith, 2014, Mental health: a world of depression, Nat News, 515, 180, 10.1038/515180a Grant, 2015, Epidemiology of DSM-5 alcohol use disorder: results from the national epidemiologic survey on alcohol and related conditions III, JAMA Psychiatry, 72, 757, 10.1001/jamapsychiatry.2015.0584 Rush, 2006, Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR D report, Am J Psychiatry, 163, 1905, 10.1176/ajp.2006.163.11.1905 Osterberg, 2005, Adherence to Medication, N Engl J Med, 353, 487, 10.1056/NEJMra050100 Berman, 2000, Antidepressant effects of ketamine in depressed patients, Biol Psychiatry, 47, 351, 10.1016/S0006-3223(99)00230-9 Romeo, 2015, Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression, Psychiatry Res, 230, 682, 10.1016/j.psychres.2015.10.032 dos Santos, 2016, Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years, Ther Adv Psychopharmacol, 6, 193, 10.1177/2045125316638008 Halberstadt, 2015, Recent advances in the neuropsychopharmacology of serotonergic hallucinogens, Behav Brain Res, 277, 99, 10.1016/j.bbr.2014.07.016 Nichols, 2016, Psychedelics, Pharmacol Rev, 68, 264, 10.1124/pr.115.011478 Sessa, 2012 Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, PLoS Med, 6, 10.1371/journal.pmed.1000100 Deeks, 2003, Evaluating non-randomised intervention studies, Health Technol Assess Winch Engl, 7 Wells, 2000 Higgins, 2011, The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, BMJ [Internet], 343 Motheral, 2003, A checklist for retrospective database studies--report of the ISPOR Task Force on Retrospective Databases, Value Health J Int Soc Pharmacoeconomics Outcomes Res, 6, 90, 10.1046/j.1524-4733.2003.00242.x Agin-Liebes, 2020, Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer, J Psychopharmacol (Oxf), 34, 155, 10.1177/0269881119897615 Gasser, 2014, Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases, J Nerv Ment Dis, 202, 513, 10.1097/NMD.0000000000000113 Griffiths, 2016, Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial, J Psychopharmacol (Oxf), 30, 1181, 10.1177/0269881116675513 Grob, 2011, Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer, Arch Gen Psychiatry, 68, 71, 10.1001/archgenpsychiatry.2010.116 Ross, 2016, Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial, J Psychopharmacol (Oxf), 30, 1165, 10.1177/0269881116675512 Osório, 2015, Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report, Rev Bras Psiquiatr Sao Paulo Braz 1999, 37, 13 Sanches, 2016, Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT Study, J Clin Psychopharmacol, 36, 77, 10.1097/JCP.0000000000000436 Santos, 2018, Long-term effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up, Arch Clin Psychiatry São Paulo, 45, 22, 10.1590/0101-60830000000149 Palhano-Fontes, 2019, Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial, Psychol Med, 49, 655, 10.1017/S0033291718001356 Zeifman, 2019, The impact of ayahuasca on suicidality: results from a randomized controlled trial, Front Pharmacol [Internet], 10 Carhart-Harris, 2016, Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study, Lancet Psychiatry, 3, 619, 10.1016/S2215-0366(16)30065-7 Carhart-Harris, 2018, Psilocybin with psychological support for treatment-resistant depression: six-month follow-up, Psychopharmacology (Berl), 235, 399, 10.1007/s00213-017-4771-x Erritzoe, 2018, Effects of psilocybin therapy on personality structure, Acta Psychiatr Scand, 138, 368, 10.1111/acps.12904 Lyons, 2018, More realistic forecasting of future life events after psilocybin for treatment-resistant depression, Front Psychol, 9, 1721, 10.3389/fpsyg.2018.01721 Stroud, 2018, Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression, Psychopharmacology (Berl), 235, 459, 10.1007/s00213-017-4754-y Davis, 2020, Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial, JAMA Psychiatry Bogenschutz, 2015, Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study, J Psychopharmacol Oxf Engl, 29, 289, 10.1177/0269881114565144 Garcia-Romeu, 2019, Cessation and reduction in alcohol consumption and misuse after psychedelic use, J Psychopharmacol Oxf Engl, 33, 1088, 10.1177/0269881119845793 Ribeiro Barbosa, 2018, Assessment of alcohol and tobacco use disorders among religious users of ayahuasca, Front Psychiatry, 9, 136, 10.3389/fpsyt.2018.00136 Thomas, 2013, Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada, Curr Drug Abuse Rev, 6, 30, 10.2174/15733998113099990003 Johnson, 2014, Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction, J Psychopharmacol Oxf Engl, 28, 983, 10.1177/0269881114548296 Johnson, 2017, Long-term follow-up of psilocybin-facilitated smoking cessation, Am J Drug Alcohol Abuse, 43, 55, 10.3109/00952990.2016.1170135 Johnson, 2017, An online survey of tobacco smoking cessation associated with naturalistic psychedelic use, J Psychopharmacol Oxf Engl, 31, 841, 10.1177/0269881116684335 Garcia-Romeu, 2020, Persisting reductions in cannabis, Opioid, and stimulant misuse after naturalistic psychedelic use: an online survey, Front Psychiatry, 10, 955, 10.3389/fpsyt.2019.00955 Moreno, 2006, Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder, J Clin Psychiatry, 67, 1735, 10.4088/JCP.v67n1110 Muttoni, 2019, Classical psychedelics for the treatment of depression and anxiety: a systematic review, J Affect Disord, 258, 11, 10.1016/j.jad.2019.07.076 Andersen KAA, Carhart-Harris R, Nutt DJ, Erritzoe D. Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. Acta Psychiatr Scand [Internet]. [cité 25 nov 2020];n/a(n/a). Disponible sur: http://onlinelibrary.wiley.com/doi/abs/10.1111/acps.13249. Dos Santos, 2016, Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Ther, Adv Psychopharmacol, 6, 193, 10.1177/2045125316638008 Santos, 2018, Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews, Expert Rev Clin Pharmacol, 11, 889, 10.1080/17512433.2018.1511424 Luoma, 2020, A meta-analysis of placebo-controlled trials of psychedelic-assisted therapy, J Psychoactive Drugs, 0, 1 Romeo, 2020, Efficacy of psychedelic treatments on depressive symptoms: a meta-analysis, J Psychopharmacol Oxf Engl, 10.1177/0269881120919957 Goldberg, 2020, The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis, Psychiatry Res, 284, 112749, 10.1016/j.psychres.2020.112749 Bogenschutz, 2015, Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study, J Psychopharmacol Oxf Engl, 29, 289, 10.1177/0269881114565144 Delay, 1949, Sur les explorations pharmacodynamiques en psychiatrie: narco-analyse et choc amphetaminique, Proc R Soc Med, 42, 491 Carhart-Harris, 2018, Psychedelics and the essential importance of context, J Psychopharmacol (Oxf), 32, 725, 10.1177/0269881118754710 Schenberg, 2018, Psychedelic-assisted psychotherapy: a paradigm shift in psychiatric research and development, Front Pharmacol [Internet], 9 Roseman, 2018, Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression, Front Pharmacol [Internet], 8 Madsen, 2019, Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels, Neuropsychopharmacology, 44, 1328, 10.1038/s41386-019-0324-9 Preller, 2017, The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation, Curr Biol, 27, 451, 10.1016/j.cub.2016.12.030